Is XRAY or CERS more profitable?

Cerus has a net margin of -3.06% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets DENTSPLY SIRONA -14.99% 20.84% 5.32% Cerus -3.06% -10.19% -3.14%

Does the media favor XRAY or CERS?

In the previous week, DENTSPLY SIRONA had 7 more articles in the media than Cerus. MarketBeat recorded 9 mentions for DENTSPLY SIRONA and 2 mentions for Cerus. Cerus' average media sentiment score of 0.51 beat DENTSPLY SIRONA's score of 0.10 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DENTSPLY SIRONA 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AVNS or CERS?

Cerus has a consensus target price of $5.25, indicating a potential upside of 101.92%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cerus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is AVNS or CERS more profitable?

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Avanos Medical -10.39% 5.39% 3.97% Cerus -3.06% -10.19% -3.14%

Does the media refer more to AVNS or CERS?

In the previous week, Cerus had 1 more articles in the media than Avanos Medical. MarketBeat recorded 2 mentions for Cerus and 1 mentions for Avanos Medical. Cerus' average media sentiment score of 0.51 beat Avanos Medical's score of 0.21 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avanos Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QDEL or CERS more profitable?

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -39.20% 4.88% 1.63% Cerus -3.06% -10.19% -3.14%

Does the media favor QDEL or CERS?

In the previous week, QuidelOrtho had 1 more articles in the media than Cerus. MarketBeat recorded 3 mentions for QuidelOrtho and 2 mentions for Cerus. Cerus' average media sentiment score of 0.51 beat QuidelOrtho's score of 0.45 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SMTI or CERS?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 3.13 -$37.56M -$3.59 N/A Cerus $206.13M 2.54 -$15.63M -$0.03 N/A

Is SMTI or CERS more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 29.72% 2.84% Cerus -3.06% -10.19% -3.14%

Which has better valuation & earnings, EMBC or CERS?

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.29 $95.40M $1.48 3.77 Cerus $206.13M 2.54 -$15.63M -$0.03 N/A

Is EMBC or CERS more profitable?

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Cerus -3.06% -10.19% -3.14%

Does the media favor EMBC or CERS?

In the previous week, Embecta had 2 more articles in the media than Cerus. MarketBeat recorded 4 mentions for Embecta and 2 mentions for Cerus. Cerus' average media sentiment score of 0.51 beat Embecta's score of 0.34 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cerus (CERS) Competitors

$2.60 -0.07 (-2.62%)

Closing price 04:00 PM Eastern

Extended Trading

$2.63 +0.03 (+1.19%)

As of 07:30 PM Eastern

Compare

CERS vs. XRAY, AVNS, QDEL, SMTI, and EMBC

Should you buy Cerus stock or one of its competitors? Cerus's main competitors and comparable companies include DENTSPLY SIRONA (XRAY), Avanos Medical (AVNS), QuidelOrtho (QDEL), Sanara MedTech (SMTI), and Embecta (EMBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Cerus compare to DENTSPLY SIRONA?

DENTSPLY SIRONA (NASDAQ:XRAY) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Cerus has a net margin of -3.06% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DENTSPLY SIRONA	-14.99%	20.84%	5.32%
Cerus	-3.06%	-10.19%	-3.14%

DENTSPLY SIRONA has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Cerus has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

In the previous week, DENTSPLY SIRONA had 7 more articles in the media than Cerus. MarketBeat recorded 9 mentions for DENTSPLY SIRONA and 2 mentions for Cerus. Cerus' average media sentiment score of 0.51 beat DENTSPLY SIRONA's score of 0.10 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DENTSPLY SIRONA	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.7% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 5.3% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cerus has lower revenue, but higher earnings than DENTSPLY SIRONA. Cerus is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DENTSPLY SIRONA	$3.68B	0.53	-$598M	-$2.75	N/A
Cerus	$206.13M	2.54	-$15.63M	-$0.03	N/A

DENTSPLY SIRONA currently has a consensus price target of $13.31, suggesting a potential upside of 36.07%. Cerus has a consensus price target of $5.25, suggesting a potential upside of 101.92%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than DENTSPLY SIRONA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DENTSPLY SIRONA	3 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Cerus beats DENTSPLY SIRONA on 9 of the 15 factors compared between the two stocks.

How does Cerus compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Cerus has a consensus target price of $5.25, indicating a potential upside of 101.92%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cerus has lower revenue, but higher earnings than Avanos Medical. Cerus is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A
Cerus	$206.13M	2.54	-$15.63M	-$0.03	N/A

95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 2.3% of Avanos Medical shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Cerus	-3.06%	-10.19%	-3.14%

Avanos Medical has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Cerus has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

In the previous week, Cerus had 1 more articles in the media than Avanos Medical. MarketBeat recorded 2 mentions for Cerus and 1 mentions for Avanos Medical. Cerus' average media sentiment score of 0.51 beat Avanos Medical's score of 0.21 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avanos Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cerus beats Avanos Medical on 11 of the 16 factors compared between the two stocks.

How does Cerus compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

QuidelOrtho presently has a consensus target price of $13.63, indicating a potential upside of 31.77%. Cerus has a consensus target price of $5.25, indicating a potential upside of 101.92%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Cerus	-3.06%	-10.19%	-3.14%

In the previous week, QuidelOrtho had 1 more articles in the media than Cerus. MarketBeat recorded 3 mentions for QuidelOrtho and 2 mentions for Cerus. Cerus' average media sentiment score of 0.51 beat QuidelOrtho's score of 0.45 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus has lower revenue, but higher earnings than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.26	-$1.13B	-$15.41	N/A
Cerus	$206.13M	2.54	-$15.63M	-$0.03	N/A

QuidelOrtho has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Cerus has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cerus beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does Cerus compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 5.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sanara MedTech currently has a consensus price target of $35.00, indicating a potential downside of 0.43%. Cerus has a consensus price target of $5.25, indicating a potential upside of 101.92%. Given Cerus' stronger consensus rating and higher probable upside, analysts plainly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Sanara MedTech has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Cerus has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A
Cerus	$206.13M	2.54	-$15.63M	-$0.03	N/A

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Cerus	-3.06%	-10.19%	-3.14%

In the previous week, Cerus had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 2 mentions for Cerus and 0 mentions for Sanara MedTech. Cerus' average media sentiment score of 0.51 beat Sanara MedTech's score of 0.00 indicating that Cerus is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanara MedTech	Neutral
Cerus	Positive

Summary

Cerus beats Sanara MedTech on 11 of the 16 factors compared between the two stocks.

How does Cerus compare to Embecta?

Embecta (NASDAQ:EMBC) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

93.8% of Embecta shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 97.13%. Cerus has a consensus price target of $5.25, suggesting a potential upside of 101.92%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Cerus	-3.06%	-10.19%	-3.14%

Embecta has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Cerus has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

In the previous week, Embecta had 2 more articles in the media than Cerus. MarketBeat recorded 4 mentions for Embecta and 2 mentions for Cerus. Cerus' average media sentiment score of 0.51 beat Embecta's score of 0.34 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.29	$95.40M	$1.48	3.77
Cerus	$206.13M	2.54	-$15.63M	-$0.03	N/A

Summary

Embecta and Cerus tied by winning 8 of the 16 factors compared between the two stocks.

Get Cerus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERS vs. The Competition

Export

Metric	Cerus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$538.07M	$5.52B	$7.21B	$13.10B
Dividend Yield	N/A	1.79%	2.53%	13.00%
P/E Ratio	-86.67	25.27	274.58	25.69
Price / Sales	2.54	43.07	639.38	80.65
Price / Cash	N/A	32.79	76.31	52.02
Price / Book	7.65	5.78	10.44	6.32
Net Income	-$15.63M	$151.55M	$3.49B	$359.73M
7 Day Performance	2.77%	1.49%	0.51%	1.35%
1 Month Performance	-7.47%	-3.63%	-3.38%	-3.68%
1 Year Performance	62.50%	6.20%	16.04%	5.56%

Cerus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERS Cerus	1.6547 of 5 stars	$2.60 -2.6%	$5.25 +101.9%	+76.8%	$538.07M	$206.13M	N/A	345	Positive News
XRAY DENTSPLY SIRONA	3.1968 of 5 stars	$10.10 -2.7%	$13.54 +34.1%	-24.8%	$2.01B	$3.64B	N/A	14,000
AVNS Avanos Medical	0.1386 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	4,040	Positive News
QDEL QuidelOrtho	3.5158 of 5 stars	$11.11 -0.1%	$13.63 +22.7%	-61.6%	$761.53M	$2.67B	N/A	6,500
SMTI Sanara MedTech	0.5939 of 5 stars	$35.11 +0.4%	$35.00 -0.3%	+4.3%	$322.62M	$103.12M	N/A	108

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERS) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerus (CERS) Competitors

CERS vs. XRAY, AVNS, QDEL, SMTI, and EMBC

How does Cerus compare to DENTSPLY SIRONA?

Summary

How does Cerus compare to Avanos Medical?

Summary

How does Cerus compare to QuidelOrtho?

Summary

How does Cerus compare to Sanara MedTech?

Summary

How does Cerus compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cerus (CERS) Competitors

CERS vs. XRAY, AVNS, QDEL, SMTI, and EMBC

How does Cerus compare to DENTSPLY SIRONA?

Is XRAY or CERS more profitable?

Which has more volatility and risk, XRAY or CERS?

Does the media favor XRAY or CERS?

Do institutionals and insiders hold more shares of XRAY or CERS?

Which has stronger valuation and earnings, XRAY or CERS?

Do analysts recommend XRAY or CERS?

Summary

How does Cerus compare to Avanos Medical?

Do analysts recommend AVNS or CERS?

Which has higher valuation and earnings, AVNS or CERS?

Do institutionals & insiders have more ownership in AVNS or CERS?

Is AVNS or CERS more profitable?

Which has more volatility & risk, AVNS or CERS?

Does the media refer more to AVNS or CERS?

Summary

How does Cerus compare to QuidelOrtho?

Do analysts recommend QDEL or CERS?

Is QDEL or CERS more profitable?

Does the media favor QDEL or CERS?

Which has better valuation and earnings, QDEL or CERS?

Which has more risk and volatility, QDEL or CERS?

Do institutionals and insiders believe in QDEL or CERS?

Summary

How does Cerus compare to Sanara MedTech?

Do insiders and institutionals believe in SMTI or CERS?

Do analysts recommend SMTI or CERS?

Which has more risk & volatility, SMTI or CERS?

Which has higher earnings & valuation, SMTI or CERS?

Is SMTI or CERS more profitable?

Does the media favor SMTI or CERS?

Summary

How does Cerus compare to Embecta?

Do insiders and institutionals hold more shares of EMBC or CERS?

Do analysts prefer EMBC or CERS?

Is EMBC or CERS more profitable?

Which has more volatility and risk, EMBC or CERS?

Does the media favor EMBC or CERS?

Which has better valuation & earnings, EMBC or CERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools